<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="874">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149781</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT05149781</nct_id>
  </id_info>
  <brief_title>Standardized Diagnosis and Treatment of Endocrine Hypertension</brief_title>
  <official_title>Standardized Diagnosis and Treatment of Endocrine Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Nantong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Hospital of Nantong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cases of endocrine hypertension or primary hypertension who have signed informed consent will&#xD;
      be collected. Patients with endocrine hypertension will be divided into surgical treatment&#xD;
      group and drug treatment group according to actual treatment situation. A database will be&#xD;
      established for all patients. We will comprehensively evaluate the general conditions, past&#xD;
      medical history, metabolic and biochemical indicators, psychological status, cardiovascular&#xD;
      risk factors. All the patients will be followed up for 12 months at baseline, 6 months and 12&#xD;
      months. Clinical data and specimen will be collected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will collect 100 patients with secretory hypertension and 100 patients with essential&#xD;
      hypertension. Patients with endocrine hypertension will be divided into surgical treatment&#xD;
      group and drug treatment group according to actual treatment situation. Resected specimens&#xD;
      from surgical patients will be used for immunohistochemistry and western blot. A database&#xD;
      will be established for all patients to assess their general situation, past medical history,&#xD;
      metabolic and biochemical indicators, psychological status, cardiovascular risk factors, etc.&#xD;
      We expect to find more accurate screening indicators from blood and urine specimens. All the&#xD;
      patients will be followed up for 12 months at baseline, 6 months and 12 months. Blood&#xD;
      pressure, degree of atherosclerosis, biochemical markers, hormone levels and cardiac function&#xD;
      indicators will be measured at three time points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of blood pressure after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotid intima thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of carotid intima thickness after treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Endocrine Hypertension</condition>
  <arm_group>
    <arm_group_label>patients with EH</arm_group_label>
    <description>patients with endocrine hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with PH</arm_group_label>
    <description>patients with primary hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standardized diagnosis and treatment</intervention_name>
    <description>Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.</description>
    <arm_group_label>patients with EH</arm_group_label>
    <other_name>antihypertensive drugs</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, adrenal adenoma tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with endocrine hypertension or primary hypertension treated at Affiliated Hospital&#xD;
        of Nantong University between 2021 and 2024&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ageâ‰¥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. myocardial infarction&#xD;
&#xD;
          2. congestive heart failure&#xD;
&#xD;
          3. stroke&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gu Yunjuan, M.D/Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Nantong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gu Yunjuan, M.D/Ph.D</last_name>
    <phone>+8615851207860</phone>
    <email>desette@ntu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gu Yunjuan</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gu Yunjuan, M.D/Ph.D</last_name>
      <phone>+8615851207860</phone>
      <email>desette@ntu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

